CDIB Capital Healthcare Ventures’ Portfolio Company ACT Genomics Establishes Molecular Laboratory for International Customers in Asia. CDIB will continue to promote the industry investment chain to help Taiwan’s biotechnology industry reach the global stage.

Oct 18, 2021
Press Release
A portfolio company of CDIB Capital Healthcare Ventures, ACT Genomics Holdings Company Limited (ACT Genomics) recently announced a joint venture with Cerba Research, one of the largest CRO laboratories in Europe, to establish a molecular laboratory for customers in Asia. This collaboration model signifies the capability of Asian biotech firms’ management teams to be in line with international standards. ACT Genomics’ international partnership shows that the skills of Asian biotech firms’ management teams are internationally recognized. CDIB’s biomedical investment team is actively constructing a biomedical industry portfolio. Focusing on “international” and “cross-industry” services, fundraising, talent development, and information exchange platforms, the team will continue to play a key role and provide funding to domestic and foreign biomedical companies with growth potential to develop internationally.

The CDIB biomedical team stated that, in his 2015 State of the Union Address, then President Obama proposed the Precision Medicine Initiative, which involves using genetic testing to provide accurate prescriptions of treatment. In 2014, the newly-founded ACT Genomics began to take root and grow in Taiwan. With excellent investment opportunities coupled with this massive industry trend, the company has worked hard over the years to become one of Asia’s best cancer genomic testing companies in Asia serving customers in Taiwan, Hong Kong, Japan, Southeast Asia, and the UK with the world's highest standard of technology, quality, and services. ACT Genomics has an international and experienced management team, board members, and shareholders. It has carved its place in the market with exceptional technologies on par with its international peers.

Optimistic about the future of precision medicine, CDIB Capital Healthcare Ventures invested in ACT Genomics in 2016. Focusing on gene sequencing and data analysis, the company provides precise (personalized) cancer testing services. The company also interprets the genomic data to assist in cancer prevention, diagnosis, treatment, and monitoring, unlike competitors that only provide gene sequencing services, making it an important cancer precision medical information services provider on the market. This joint venture with Cerba Research to establish a molecular laboratory for Asian customers is another important milestone towards the company’s globalization and internationalization.

James Ho, Chairman of CDIB Capital Healthcare Ventures, stated that CDIB has established CDIB Capital Healthcare Ventures II, with fundraising and registration completed in December 2020. With one RMB Healthcare Fund, two NTD Healthcare Ventures, and long-term investments in support of biomedical industries, CDIB’s relevant overall management scale has exceeded NT$10 billion. CDIB has invested in nearly 30 biomedical companies covering contract development and manufacturing organization (CDMO), the development of new drugs, advanced genetic testing, gene therapy, and next-gen cell therapy. Going forward, these funds will continue to pinpoint the direction of precision healthcare and treatment. James Ho stressed that a key part of CDIB’s efforts to construct a biomedical industry portfolio along each investment chain is to promote Taiwan’s biomedical industry on the global stage. CDIB Capital Healthcare Ventures’ investment strategy focuses on biotech companies with high technological standards, growth potential, and the ability to help humanity fight major diseases, in hopes of supporting Taiwan's biotech industry.